RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Editas Medicine Stock

Editas Medicine Net Income 2024

Editas Medicine Net Income

-246.15 M USD

Ticker

EDIT

ISIN

US28106W1036

WKN

A2AC4K

In 2024, Editas Medicine's profit amounted to -246.15 M USD, a 60.65% increase from the -153.22 M USD profit recorded in the previous year.

The Editas Medicine Net Income history

YEARNET INCOME (undefined USD)
2030e-
2029e-
2028e-
2027e-
2026e-
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-
2015-
2014-
2013-

Editas Medicine Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Editas Medicine, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Editas Medicine from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Editas Medicine’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Editas Medicine. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Editas Medicine’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Editas Medicine’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Editas Medicine’s growth potential.

Editas Medicine Revenue, EBIT and net profit per share

DateEditas Medicine RevenueEditas Medicine EBITEditas Medicine Net Income
2030e1.1 B undefined98.06 M undefined-841,296.1 undefined
2029e497.77 M undefined38.11 M undefined-73.47 M undefined
2028e289.5 M undefined-113.81 M undefined-86.86 M undefined
2027e173.36 M undefined-201.06 M undefined-170.57 M undefined
2026e51.18 M undefined-284.73 M undefined-226.54 M undefined
2025e18.76 M undefined-266.21 M undefined-233.27 M undefined
2024e29.29 M undefined-241.64 M undefined-246.15 M undefined
202378.12 M undefined-169.18 M undefined-153.22 M undefined
202219.71 M undefined-225.95 M undefined-220.43 M undefined
202125.54 M undefined-193.15 M undefined-192.5 M undefined
202090.73 M undefined-134.84 M undefined-115.98 M undefined
201920.53 M undefined-140.92 M undefined-133.75 M undefined
201831.94 M undefined-113.73 M undefined-109.95 M undefined
201713.73 M undefined-119.93 M undefined-120.32 M undefined
20166.05 M undefined-97.19 M undefined-97.23 M undefined
20151.63 M undefined-35.31 M undefined-73.29 M undefined
20140 undefined-12.72 M undefined-13.99 M undefined
20130 undefined-1.74 M undefined-1.78 M undefined

Editas Medicine stock margins

The Editas Medicine margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Editas Medicine. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Editas Medicine.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Editas Medicine's sales revenue. A higher gross margin percentage indicates that the Editas Medicine retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Editas Medicine's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Editas Medicine's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Editas Medicine's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Editas Medicine. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Editas Medicine's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Editas Medicine Margin History

Editas Medicine Gross marginEditas Medicine Profit marginEditas Medicine EBIT marginEditas Medicine Profit margin
2030e0 %8.89 %-0.08 %
2029e0 %7.66 %-14.76 %
2028e0 %-39.31 %-30 %
2027e0 %-115.98 %-98.39 %
2026e0 %-556.37 %-442.67 %
2025e0 %-1,419.42 %-1,243.78 %
2024e0 %-824.92 %-840.31 %
20230 %-216.56 %-196.13 %
20220 %-1,146.37 %-1,118.37 %
20210 %-756.26 %-753.72 %
20200 %-148.62 %-127.83 %
20190 %-686.41 %-651.49 %
20180 %-356.07 %-344.24 %
20170 %-873.49 %-876.33 %
20160 %-1,606.45 %-1,607.11 %
20150 %-2,166.26 %-4,496.32 %
20140 %0 %0 %
20130 %0 %0 %

Editas Medicine Aktienanalyse

What does Editas Medicine do?

Editas Medicine Inc. is a rising biopharmaceutical company specializing in the development of groundbreaking therapies based on genome editing. Its goal is to combat genetic diseases and other genetically related disorders by selectively modifying DNA sequences. The company was founded in 2013 by a group of renowned scientists, including prominent genome editors Jennifer Doudna and George Church. Over the years, Editas Medicine Inc. has established itself as a pioneer in the field of genome editing and has received numerous awards and funding. Its business model revolves around researching and developing innovative therapies based on genetic modifications, using approaches such as CRISPR/Cas9, TALEN, and zinc finger nucleases. The company aims to develop treatments for previously incurable, severe diseases. Its activities are divided into various business areas, including the exploration of gene therapies, the development of medications based on CRISPR/Cas9 technology, and the research of genome-based diagnostic options. Editas Medicine Inc. has already introduced some products to the market or is in advanced stages of development, such as the medication LCA10 for a rare form of blindness and the medication CEP290 for a severe genetic disease. Overall, Editas Medicine Inc. has experienced remarkable growth in recent years, becoming one of the key players in genome editing. The market for gene therapies and genome-based treatments has significant growth potential, making the company's prospects promising. Editas Medicine Inc. is dedicated to advancing genomic medicine by developing groundbreaking solutions for incurable diseases and providing a platform for new technologies in the market. Editas Medicine ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Editas Medicine's Profit Margins

The profit margins of Editas Medicine represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Editas Medicine's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Editas Medicine's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Editas Medicine's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Editas Medicine’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Editas Medicine stock

How much profit has Editas Medicine made this year?

Editas Medicine has made -246.15 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 60.65% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Editas Medicine publish its earnings?

Editas Medicine publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Editas Medicine?

The profits of Editas Medicine are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Editas Medicine?

You can learn more about the earnings of Editas Medicine by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Editas Medicine pay?

Over the past 12 months, Editas Medicine paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Editas Medicine is expected to pay a dividend of 0 USD.

What is the dividend yield of Editas Medicine?

The current dividend yield of Editas Medicine is .

When does Editas Medicine pay dividends?

Editas Medicine pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Editas Medicine?

Editas Medicine paid dividends every year for the past 0 years.

What is the dividend of Editas Medicine?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Editas Medicine located?

Editas Medicine is assigned to the 'Health' sector.

Wann musste ich die Aktien von Editas Medicine kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Editas Medicine from 9/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/8/2024.

When did Editas Medicine pay the last dividend?

The last dividend was paid out on 9/8/2024.

What was the dividend of Editas Medicine in the year 2023?

In the year 2023, Editas Medicine distributed 0 USD as dividends.

In which currency does Editas Medicine pay out the dividend?

The dividends of Editas Medicine are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Editas Medicine stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Editas Medicine

Our stock analysis for Editas Medicine Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Editas Medicine Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.